Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system

European Heart Journal - Cardiovascular Pharmacotherapy · Published 2026-01-20 · DOI 10.1093/ehjcvp/pvag006

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1093/ehjcvp/pvag006

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies · Frontiers in Cardiovascular Medicine · 2026 · Cites or is cited by this article
• Beta-blockers after myocardial infarction: time to change the guidelines · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Why does research integrity affect us all? · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Innovation and constraints in cardiovascular pharmacotherapy · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Why cardio-rheumatology? · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal
• Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Real-world evidence of finerenone in Type 2 diabetes: addressing confounding and follow-up duration · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal
• Different aspects of myocardial intervention and pharmacological treatment · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal